| 03-28-2011 05:12 PM CET - Health & Medicine |
|
curasan AG: Novel bone regeneration material approved for sale in Europe
Press release from: curasan AG
PR Agency: fr
(openPR) - Kleinostheim, Germany – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products”, stated Hans Dieter Rössler, CEO. Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012. www.curasan.com
curasan AG
Andrea Weidner
Lindigstrasse 4
63801 Kleinostheim
Germany
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Gutleutstraße 75
60329 Frankfurt/Main
Germany
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products”, stated Hans Dieter Rössler, CEO. Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012. www.curasan.com
curasan AG
Andrea Weidner
Lindigstrasse 4
63801 Kleinostheim
Germany
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Gutleutstraße 75
60329 Frankfurt/Main
Germany
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
News-ID: 168559
|
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
curasan AG
Comments about openPR
Your portal is fast, simple, and easy to use. Others may have more functions but they also demand more editing time, you have to preformat the text in order to achieve a good result etc.
I think openPR is really fantastic!
Andreas Knepper, wallmedien AG
I think openPR is really fantastic!
Andreas Knepper, wallmedien AG